HS-729
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
HS-729 |
Humane Rhabdomyosarkom Zell-Linie |
300443 |
cryovial |
265,00 |
HS-729 |
Humane Rhabdomyosarkom Zell-Linie |
330443 |
vital |
335,00 |
| Designation: | HS-729 |
| ATCC Number: | HTB-153 |
| Depositor: | Owens |
| Organism: | Homo sapiens (human) |
| Ethnicity: | caucasian |
| Age/Stage: | 74 years |
| Gender: | male |
| Tissue: | rhabdomyosarcoma |
| Morphology: | fibroblast |
| Growth Properties: | monolayer |
| Culture Medium: | Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; fetal bovine serum, 10% |
| Subculturing: | Remove medium, rinse with fresh 0.025% trypsin, 0.02% EDTA solution, remove trypsin and let the culture sit at room temperature (or at 37°C) until the cells detach (about 10 minutes). Add fresh medium, aspirate and dispense into new flasks. |
| Split Ratio: | A ratio of 1:2 to 1:3 is recommended |
| Fluid Renewal: | 2 to 3 times weekly |
| Freeze Medium: | CM-1, Cell Lines Service |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| DNA Profile (STR): | Amelogenin: X,Y CSF1PO: 10 D13S317: 11 D16S539: 11 D5S818: 11,12 D7S820: 8,9 TH01: 6,9.3 TPOX: 11 vWA: 16,17 D3S1358: 17 D21S11: 28,31.2 D18S51: 12 Penta E: 7,12 Penta D: 9,14 D8S1179: 10,14 FGA: 19,20 CLS – Cell Lines Service 2010. |
| Isoenzymes: | G6PD, B |
References: The effect of 1, 25-dihydroxyvitamin D3 on the growth of soft-tissue sarcoma cells as mediated by the vitamin D receptor. Shabahang-M; Buffan-AE; Nolla-JM; Schumaker-LM; Brenner-RV; Buras-RR; Nauta-RJ; Evans-SR Ann-Surg-Oncol. 1996 Mar; 3(2): 144-9 BACKGROUND: Soft-tissue sarcomas, malignant neoplasms originating from mesenchymal tissue, are rare but highly aggressive tumors. Present modes of therapy are associated with high rates of recurrence. 1, 25-Dihydroxyvitamin D3, the active metabolite of vitamin D, serves as a potent antiproliferative agent in human cancer cells. METHODS: In this study, six soft-tissue sarcoma cell lines were analyzed for vitamin D receptor (VDR) expression, which was then correlated with the degree of growth inhibition in response to 1, 25-dihydroxyvitamin D3. These cell lines included rhabdomyosarcoma (HS729, A204), fibrosarcoma (HS913t), synovial sarcoma (SW982), liposarcoma (SW872), and leiomyosarcoma (SKLMS-1). The level of VDR messenger RNA (mRNA) expression was determined using a ribonuclease protection assay, and functional receptor content was determined by using a ligand-binding assay. Growth studies, including [3H]thymidine uptake and growth curves, were performed on two of the six cell lines that expressed the highest and lowest receptor levels. RESULTS: Ribonuclease protection and ligand-binding assays demonstrated variable levels of VDR, with HS729 showing high expression and A204 showing no expression. In HS729, [3H]thymidine uptake was significantly decreased at 10(-7) M (33%) and 10(-6) M (40%) 1, 25-dihydroxyvitamin D3. Growth curve studies showed significant growth inhibition of 55% at 10(-6) M. A204 cells showed no growth inhibition upon treatment with 1, 25-dihydroxyvitamin D3. CONCLUSION: This study demonstrates the existence of VDR in soft-tissue sarcoma cells and suggests a correlation between the level of VDR in cells and the degree of growth inhibition caused by 1, 25-dihydroxyvitamin D3 which may potentially serve as an alternative form of therapy for soft-tissue sarcomas. | |
